View Older Stories View More Recent Stories

May 31, 2022 12:59AM FDA Accepts Dupixent® (dupilumab) for Priority Review in Adults with Prurigo Nodularis
May 20, 2022 03:15PM Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
May 20, 2022 03:15PM FDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis
Apr 7, 2022 01:00AM Press Release: Dupixent® (dupilumab) approved by European Commission for children aged 6 to 11 years with severe asthma with type 2 inflammation
Apr 7, 2022 12:59AM Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
Apr 4, 2022 01:00AM Press Release: FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis
Mar 26, 2022 10:00AM Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
Mar 26, 2022 09:59AM Late-breaking Phase 3 Data at AAD 2022 Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Prurigo Nodularis
Mar 16, 2022 06:30AM Seagen and Sanofi Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates
Mar 16, 2022 06:18AM Press Release: Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates
Feb 26, 2022 12:05PM Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis
Feb 26, 2022 12:04PM Late-breaking Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Eosinophilic Esophagitis
Feb 26, 2022 12:00PM Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria
Feb 18, 2022 01:00AM Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program
Feb 10, 2022 01:00AM FDA accepts Dupixent® (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
Jan 31, 2022 01:00AM CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation
Jan 19, 2022 01:00AM Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis
Jan 7, 2022 01:00AM Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines
Dec 13, 2021 01:00AM Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking session
Dec 8, 2021 05:30PM New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma
Nov 18, 2021 01:30AM Sanofi invests $180 million equity in Owkin’s artificial intelligence and federated learning to advance oncology pipeline
Oct 25, 2021 01:00AM Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease
Oct 22, 2021 01:00AM Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease
Oct 20, 2021 05:30PM FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma
Sep 21, 2021 01:00AM New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV
Sep 19, 2021 11:30AM ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC
Aug 30, 2021 01:00AM Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in ch
Aug 5, 2021 06:00AM Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer
Jul 29, 2021 01:00AM Dupixent® (dupilumab) significantly improved itch and hives in patients with chronic spontaneous urticaria, a step forward in demonstrating the role of type 2 inflammation in these patients  
Jun 28, 2021 01:00AM Dupixent® (dupilumab) SmPC updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitis
Jun 25, 2021 01:15AM Sanofi: Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma
Jun 25, 2021 01:00AM Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD-L1 expression
Jun 1, 2021 06:45AM Sanofi and Merck's first and only six-in-one pediatric combination vaccine now available in the United States
May 17, 2021 10:00AM Les données d’un essai pivot présentées au Congrès 2021 de l’ATS montrent que Dupixent® (dupilumab) réduit significativement les crises d’asthme chez l’enfant et améliore sa fonction re
Apr 19, 2021 05:36AM Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE
Mar 15, 2021 02:00AM Arrêt prématuré de l’essai de phase III consacré à Libtayo® (cémiplimab) en monothérapie dans le traitement du cancer du col de l’utérus en raison d'un résultat positif en matière
Mar 4, 2021 01:00AM La FDA accepte d’examiner Dupixent® (dupilumab) dans le traitement de l’asthme modéré à sévère de l’enfant
Feb 22, 2021 01:00PM FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
Feb 12, 2021 01:00AM The Lancet publishes Libtayo® (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ³50%
Feb 9, 2021 05:15PM La FDA approuve Libtayo® (cemiplimab-rwlc), premier médicament d’immunothérapie indiqué pour le traitement des patients atteints d’un carcinome basocellulaire au stage avancé
Feb 2, 2021 01:00PM Santander Consumer USA Partners with Operation HOPE to Provide Financial Wellness Program for Employees
Nov 30, 2020 01:00AM Dupixent® (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis
Oct 26, 2020 08:00AM Dupixent® (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings
Oct 16, 2020 08:00AM CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis
Oct 13, 2020 01:00AM Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial
Sep 24, 2020 10:00AM Santander Bank Adopts Digital Mortgage And Home Equity Solution From Roostify
Sep 21, 2020 08:25AM Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
Sep 20, 2020 08:25PM Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
Sep 18, 2020 03:05AM Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO 
Sep 14, 2020 01:00AM FDA grants Dupixent® (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis
View More Recent Stories View Older Stories